--- title: "Employers are cutting GLP-1 coverage; Novo Nordisk sells Wegovy outside insurance for $149 to $199 a month" description: "Employer plans are cutting GLP-1 coverage at the fastest health-cost pace since 2003, and Novo's answer is to route the same patients outside insurance through Andel, a checkout rail it shares with rival Eli Lilly. Novo reports Q3 on November 4 with consensus at $0.73 per ADR on $11.08 billion." publisher: "The Inference" section: "Health" published: 2026-11-02T16:08:22.151Z modified: 2026-11-02T16:08:22.151Z canonical: https://theinference.org/article/employers-are-cutting-glp-1-coverage-novo-nordisk-sells-wegovy-outside-insurance-for-149-to-199-a-month language: en keywords: "Novo Nordisk, Eli Lilly, GLP-1, Drug Pricing, Healthcare" --- # Employers are cutting GLP-1 coverage; Novo Nordisk sells Wegovy outside insurance for $149 to $199 a month > Employer plans are cutting GLP-1 coverage at the fastest health-cost pace since 2003, and Novo's answer is to route the same patients outside insurance through Andel, a checkout rail it shares with rival Eli Lilly. Novo reports Q3 on November 4 with consensus at $0.73 per ADR on $11.08 billion. Employers are pulling GLP-1 coverage out of their health plans in 2027 open enrollment, and [Novo Nordisk](https://theinference.org/markets/companies/novo-nordisk), the maker of Wegovy, has answered with a door that runs around the plan [3]. [On October 28 it partnered with Andel](https://www.prnewswire.com/news-releases/andel-collaborates-with-novo-to-bring-wegovy-injection-and-wegovy-pill-direct-to-employers-302921477.html), a direct-to-employer marketplace, to let companies subsidize Wegovy, the higher-dose Wegovy HD and the once-daily Wegovy pill outside the PBM, on tax-free dollars rather than insurance [3]. ## Fewer employers cover the drugs every year [A WTW survey of companies with more than 100 workers](https://www.ajmc.com/view/as-employers-pull-back-on-glp-1s-andel-and-novo-offer-a-workaround) found 53% still cover GLP-1s for weight loss, down from 57% in 2025 and the first decline in three years; another 16% cover them but are considering removal, up from 9% [1]. The driver is cost: Marsh's survey of over 1,800 employers projects 2027 health benefit costs up 8.2%, the largest rise since 2003, and GLP-1 use alone accounts for a full percentage point of that growth [1]. About 8% of employers already steer workers to cash channels like NovoCare or LillyDirect, and 28% more are planning or considering it [1]. *Chart: **Employer GLP-1 coverage falls for the first time in three years** Range chart comparing 2025 and 2026 WTW survey shares for employers covering GLP-1s for weight loss and employers covering but considering removal.* *WTW annual survey of employers with 100-plus workers, fielded summer 2026, 2025 vs 2026 shares. Source: AJMC citing WTW [1]; CNBC [4]. [1][4]* ## Novo's checkout is also Lilly's checkout The Andel rail is not exclusive. Its founder and chief executive Jay Bregman said in May that the platform already worked with [Eli Lilly](https://theinference.org/markets/companies/eli-lilly)'s Employer Connect program, so both drugmakers are using the same pipe to reach patients whose plans dropped them [1]. Each employer sets its own contribution, month to month, from about $100 per fill to 100% of the bill [1]. Andel is explicit that its discount drug program is not insurance and participants pay the discounted charges themselves [3]. That matters because the price patients land on is the manufacturer's cash list, and Novo has flagged it as promotional: $149 a month for the Wegovy pill and $199 for the injection, [pricing that may be modified or canceled in 2027](https://www.cnbc.com/2026/10/27/glp1-drug-coverage-weight-loss-options.html) [4]. The employee carries that risk, not the employer. ## The volume stays with the drugmakers either way Meanwhile the money keeps moving to Lilly. [Its third-quarter revenue hit $24.4 billion, up 39%](https://startupfortune.com/eli-lilly-tops-1-trillion-as-novo-nordisk-eats-the-losses-of-a-drug-war/), and its market value sat near $1.26 trillion on October 30 [2]. [Novo's own filings show the stall](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278): quarterly revenue of about $12.0 billion in Q2 2026, down 0.8% from a year earlier [5]. The test comes on November 4, when Novo reports Q3: consensus is near $0.73 per ADR on $11.08 billion, after February's warning that 2026 sales and operating profit could fall 5% to 13%, which erased about $50 billion in market value [2]. *Chart: **Lilly's revenue pulls away while Novo stalls around $12 billion a quarter** Line chart of Eli Lilly and Novo Nordisk quarterly revenue from Q3 2024 through Q3 2026.* *Quarterly revenue, USD billions, from each company's SEC filings as retrieved November 2, 2026. Novo Q3 2026 not yet reported (due November 4). Sources: company_series SEC filings [5], [6]. [5][6]* ## Priced for a floor, waiting for proof If the new direct-to-employer rails fill the gap the plans leave, the worst may be priced into a stock down about 20% over twelve months while [Lilly is up about 68%](https://theinference.org/article/eli-lilly-hits-a-record-high-one-week-before-the-quarter-that-tests-ricks-s-volume-bet) [2]. If employers keep retreating faster than the cash channels grow, the retreat shows up as a Novo and Lilly revenue problem instead of a benefits story. The market has already picked its winner; November 4 tells whether the floor is real [2]. ## Takeaway Employer GLP-1 coverage fell to 53% of large companies, the first drop in three years, and 2027 health costs are projected up 8.2%, the most since 2003. Novo and Lilly now sell Wegovy direct to employers on the same Andel checkout rail at $149 to $199 a month, and Novo's November 4 Q3 report (consensus $0.73 per ADR, $11.08 billion) shows whether the cash channels hold the floor. ## Sources 1. [The American Journal of Managed Care, As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround, 2 November 2026](https://www.ajmc.com/view/as-employers-pull-back-on-glp-1s-andel-and-novo-offer-a-workaround) 2. [Startup Fortune, Eli Lilly tops $1 trillion as Novo Nordisk eats the losses of a drug war, 2 November 2026](https://startupfortune.com/eli-lilly-tops-1-trillion-as-novo-nordisk-eats-the-losses-of-a-drug-war/) 3. [PR Newswire, Andel Collaborates With Novo To Bring Wegovy Injection and Wegovy Pill Direct-to-Employers, 28 October 2026](https://www.prnewswire.com/news-releases/andel-collaborates-with-novo-to-bring-wegovy-injection-and-wegovy-pill-direct-to-employers-302921477.html) 4. [CNBC, GLP-1 drug coverage is being dropped by employer plans: What to know about 2027 weight-loss options, 27 October 2026](https://www.cnbc.com/2026/10/27/glp1-drug-coverage-weight-loss-options.html) 5. [Novo Nordisk, quarterly figures from its SEC filings, retrieved 2 November 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278) 6. [Eli Lilly, quarterly figures from its SEC filings, retrieved 2 November 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478) --- Employers are cutting GLP-1 coverage; Novo Nordisk sells Wegovy outside insurance for $149 to $199 a month — The Inference. Canonical: https://theinference.org/article/employers-are-cutting-glp-1-coverage-novo-nordisk-sells-wegovy-outside-insurance-for-149-to-199-a-month